Special Issue "Anti-Obesity Drugs"
A special issue of Pharmaceuticals (ISSN 1424-8247).
Deadline for manuscript submissions: closed (31 January 2013)
Dr. Raj Padwal
Faculty of Medicine & Dentistry, 2J2.00 WC Mackenzie Health Sciences Centre, University of Alberta, 8440 112 Street NW, Edmonton, AB T6G 2B7, USA
Interests: antiobesity drugs; bariatric surgery; bariatric care; hypertension; health outcomes research
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. Papers will be published continuously (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are refereed through a peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Pharmaceuticals is an international peer-reviewed Open Access monthly journal published by MDPI.
- antiobesity drug
- lipase inhibitor
- endocannabinoid receptor blocker
- beta-3 blocker
- adrenergic reuptake inhibitor
- serotonin agonist
Pharmaceuticals 2010, 3(12), 3494-3521; doi:10.3390/ph3123494
Received: 5 October 2010; in revised form: 17 November 2010 / Accepted: 23 November 2010 / Published: 24 November 2010| Cited by 5 | PDF Full-text (294 KB) | HTML Full-text | XML Full-text
Pharmaceuticals 2010, 3(8), 2398-2415; doi:10.3390/ph3082398
Received: 8 June 2010; in revised form: 9 July 2010 / Accepted: 15 July 2010 / Published: 27 July 2010| Cited by 2 | PDF Full-text (188 KB) | HTML Full-text | XML Full-text
Review: Approved and Off-Label Uses of Obesity Medications, and Potential New Pharmacologic Treatment Options
Pharmaceuticals 2010, 3(1), 125-145; doi:10.3390/ph3010125
Received: 8 November 2009; in revised form: 7 January 2010 / Accepted: 11 January 2010 / Published: 12 January 2010| Cited by 2 | PDF Full-text (261 KB) | HTML Full-text | XML Full-text
The below list represents only planned manuscripts. Some of these manuscripts have not been received by the Editorial Office yet. Papers submitted to MDPI journals are subject to peer-review.
Manuscript ID: Pharmaceuticals-antiobsi-20090905-Tzotzas-gr
Type of Paper: Review
Title: The Effect of Incretin-Based Pharmacotherapy on Body Weight
Author: Spiridon Karras, Gerasimos Krassas and Themistoklis Tzotzas; E-Mail: firstname.lastname@example.org
Abstract: Incretin–based pharmacotherapy, represented by Glucagon-Like Peptide-1(GLP-1) mimetics and DPP-4 inhibitors, offers a new therapeutic approach in Type 2 Diabetes Mellitus (T2DM).These glucosemodulatory agents enhance insulin secretion, lower fasting and postprandial glucose, suppress glucagon secretion and may have pleiotropic metabolic effects; additionally, they participate in the reduction of gastric emptying. Clinical studies demonstrated that GLP-1 mimetics increase postprandial satiety leading to reduced food intake and weight loss. These drugs induce food intake suppression mediated by distinct, but overlapping, peripheral and central pathways. On the contrary, DPP-4 inhibitors have a weight neutral effect. This review summarizes the current knowledge on the effect of incretin–based pharmacotherapy on body weight in T2DM and proposes an integrated model of the incretins on food intake .
Last update: 13 August 2012